Trial Profile
Phase I, Open-Label, Multi-Center, Dose Escalation With Expansion Trial of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy in Relapse/Refractory Subjects With Pancreatic Cancer or Other CA19-9 Positive Malignancies
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 24 Apr 2023
Price :
$35
*
At a glance
- Drugs MVT 1075 (Primary) ; MVT 5873 (Primary)
- Indications Adenocarcinoma; Colon cancer; Lung cancer; Pancreatic cancer
- Focus Adverse reactions; First in man
- Sponsors BioNTech; MabVax Therapeutics
- 19 Apr 2023 Status changed from suspended to discontinued.
- 19 Oct 2022 Planned End Date changed from 1 Sep 2022 to 1 Feb 2023.
- 19 Oct 2022 Planned primary completion date changed from 1 Sep 2022 to 1 Feb 2023.